- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01017614
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
November 22, 2012 updated by: Pharmacosmos A/S
A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Oligosaccharide (Monofer®) Administered by Infusions or Repeated Bolus Injections in Comparison With Oral Iron Sulphate in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
The purpose of the trial is to demonstrate that intravenous iron oligosaccharide is non-inferior to oral iron sulphate in reducing iron deficiency anaemia secondary to inflammatory bowel disease (IBD), evaluated as the ability to increase haemoglobin (Hb).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study is designed to determine the effects of an investigational drug Monofer in subjects with Inflammatory Bowel Disease (IBD) (an intestinal disease characterized by swelling, redness and sometimes ulcers in intestine) and with Iron Deficiency Anaemia (IDA) (Anaemia is a condition characterized by deficiency of blood in the body).
Study Type
Interventional
Enrollment (Anticipated)
350
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aalborg, Denmark
- Research Site
-
Copenhagen, Denmark
- Research Site
-
Århus, Denmark
- Research Site
-
-
-
-
-
Hyderabad, India
- Research Site
-
Jaipur, India
- Research Site
-
Mumbai, India
- Research Site
-
Nasik, India
- Research Site
-
New Delhi, India
- Research Site
-
Pune, India
- Research Site
-
-
-
-
-
London, United Kingdom
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Subjects with a diagnosis of IBD with iron deficiency anaemia will be included if they meet all of the following criteria:
- Men and women, aged more than 18 years.
- Subjects diagnosed with inflammatory bowel disease and mild to moderate disease activity (defined as a score of less than or equal to 5 on the Harvey-Bradshaw index for Crohn's disease and a Mayo score (subscore without endoscopy) of less than or equal to 6 for ulcerative colitis).
- Hb <12.0 g/dL (7.45 mmol/L).
- Transferrin saturation (TfS) <20 %.
Exclusion Criteria:
- Anaemia predominantly caused by other factors than iron deficiency anaemia.
- Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis).
- Drug hypersensitivity (i.e. previous hypersensitivity to Iron Dextran or iron mono- or disaccharide complexes or to iron sulphate).
- Known hypersensitivity to any excipients in the investigational drug products.
- Subjects with a history of multiple allergies.
- Active Intestinal Tuberculosis.
- Active Intestinal amoebic infections.
- Decompensated liver cirrhosis and hepatitis (alanine aminotransferase (ALT) > 3 times upper limit normal).
- Acute infections (assessed by clinical judgement), supplied with white blood cells (WBC) and C-reactive protein (CRP)).
- Rheumatoid arthritis with symptoms or signs of active joint inflammation.
- Pregnancy and nursing
- Extensive active bleeding necessitating blood transfusion.
- Planned elective surgery during the study.
- Participation in any other clinical study within 3 months prior to screening.
- Intolerance to oral iron treatment.
- Untreated B12 or folate deficiency.
- Other I.V. or oral iron treatment or blood transfusion within 4 weeks prior to screening visit.
- Erythropoetin treatment within 8 weeks prior to screening visit.
- Diagnosis of Hepatitis B and/or C, confirmed by appropriate lab test.
- Any other medical condition that, in the opinion of Investigator, may cause the patient to be unsuitable for the completion of the study or place the patient at potential risk from being in the study. Example, Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
- History of immunocompromise, including positive HIV test result
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Monofer
|
|
Active Comparator: Iron Sulphate
tablets administered orally
|
200 mg daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Hb concentration from baseline to week 8.
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects who achieve target limits of Hb (men 13-18 g/dL, women 12-16 g/dL) and have change in Hb concentration > 1.0 g/dL and have serum ferritin (100-800µg/L) and have achieved Transferrin saturation (TfS) (20-50 %) at week 2, 4 and 8.
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Pharmacosmos A/S, Pharmacosmos A/S, Roervangsvej 30, DK 4300 Holbaek, Denemark
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
July 1, 2012
Study Completion (Actual)
August 1, 2012
Study Registration Dates
First Submitted
November 19, 2009
First Submitted That Met QC Criteria
November 19, 2009
First Posted (Estimate)
November 20, 2009
Study Record Updates
Last Update Posted (Estimate)
November 27, 2012
Last Update Submitted That Met QC Criteria
November 22, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P-Monofer-IBD-01
- EudraCT no 2009-012544-16
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Disease
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
Kyungpook National University HospitalDaegu Catholic University Medical Center; Yeungnam University Hospital; DongGuk...RecruitingIdiopathic Chronic Inflammatory Bowel DiseaseKorea, Republic of
-
Assiut UniversityUnknownHepatobilliary Manifestations in Inflammatory Bowel Disease Patients
Clinical Trials on Monofer
-
Pharmacosmos A/SCompleted
-
University of GlasgowPharmacosmos A/S; British Heart Foundation; NHS Greater Glasgow and ClydeCompletedChronic Heart Failure | Iron Deficiency | Left Ventricular Systolic DysfunctionUnited Kingdom
-
Pharmacosmos A/SCompletedAnemia, Iron-Deficiency | Chronic Kidney DiseaseDenmark
-
Pharmacosmos A/SCompleted
-
Qianfoshan HospitalRecruitingIron Deficiency Anemia of Pregnancy | Iron Storage DiseaseChina
-
Ministry of Health, MalaysiaUniversity of MalayaUnknown
-
Pharmacosmos A/SMax NeemanCompleted
-
Pharmacosmos A/SClinSmartCompleted
-
Pharmacosmos A/SRecruitingIron Deficiency, Anaemia in ChildrenUnited States
-
Yonsei UniversityNot yet recruitingKidney Failure, ChronicKorea, Republic of